SDEA in Pharmacovigilance: Roles, Responsibilities and Timelines

Modern pharmaceutical companies often work with multiple vendors, distributors, and licensing partners. Safety information may also come from many different sources. Without clear rules, case processing can face delays, missed deadlines, and inconsistent assessments. An effective agreement defines how information is collected, shared, processed, and escalated between parties. It also establishes responsibilities and timelines across the relevant pharmacovigilance activities. This structure helps organisations maintain oversight across complex product and partnership networks while supporting consistent processes and ensuring patient safety.

What Is a Safety Data Exchange Agreement?

A safety data exchange agreement (SDEA) is a documented framework for sharing safety information between two or more parties. It may cover development, supply, distribution, licensing, or external service arrangements for a medicinal product. The document can define responsibilities between a marketing authorisation holder, licensing partners, distributors, CROs, and service providers. It establishes how each party receives, assesses, documents, and transfers information. A pharmacovigilance agreement does not replace an organisation’s existing pharmacovigilance system. Instead, it establishes operational rules for communication and coordination. This approach clarifies party responsibility when several entities contribute to safety oversight.

Why Are Safety Data Exchange Agreements Important for MAHs?

For MAHs, clear arrangements help ensure regulatory compliance and maintain oversight of delegated work. This becomes particularly important when organisations use pharmacovigilance outsourcing. Operational tasks may then be distributed across several organisations. However, the MAH remains accountable for its pharmacovigilance obligations.

A well-structured agreement can help MAHs:

• establish communication channels and reporting responsibilities
• define escalation routes for urgent or incomplete information
• support effective oversight of external partners
• document the controls applied throughout the product lifecycle

These provisions help prevent delays when information requires assessment or regulatory action. They also clarify expectations between organisations and provide documented evidence that agreed processes are in place.

What Information Is Covered?

The agreement should define which types of safety and regulatory information must be exchanged. It should also specify the procedures, sources, and timelines applicable to each type of information.

Individual Case Safety Reports

ICSRs may involve serious adverse events, adverse reactions, special situations, and follow-up information. The agreement should explain how cases are identified, documented, transferred, and followed up. It should also specify when partners must report adverse events to the responsible safety team. Clear procedures support consistent ICSR management and help maintain an effective case workflow.

The scope should cover suspected adverse reactions and relevant source information. It may also define contact details for case notifications and follow-up communication.

Aggregate Safety Information

The agreement may cover aggregate safety reports, including periodic safety update reports and emerging safety signals. It should identify which party prepares, reviews, and distributes each report. Responsibilities for signal detection should also be clearly defined.

Risk management plans may require specific information from partners. The agreement should explain how relevant findings are communicated and incorporated into ongoing assessments. These processes help maintain an up-to-date benefit-risk profile for the product.

Product and Regulatory Information

The scope should identify the products, territories, and applicable reporting requirements. It should also define interactions with regulatory, health, and competent authorities. Different markets may impose different requirements for information exchange and regulatory submission.

The agreement can also address product complaints and medical information received through commercial channels. These sources may provide information requiring pharmacovigilance assessment. Clear requirements help ensure that relevant information reaches the appropriate team.

Key Roles and Responsibilities

An effective agreement clearly allocates pharmacovigilance responsibilities between the parties involved. This supports consistent processes when work is divided across multiple organisations. For companies requiring additional support, pharmacovigilance consultancy services can complement internal expertise.

Responsibilities of the Marketing Authorisation Holder

The MAH maintains oversight of the pharmacovigilance system and applicable compliance requirements. It should define partner oversight, reporting responsibilities, and escalation mechanisms. The MAH should also determine how performance is monitored and how identified gaps are addressed.

The agreement should reflect the MAH’s legal obligations. It should establish controls for delegated tasks without transferring ultimate accountability to another organisation.

Responsibilities of Partners, Distributors, and Vendors

Partners should support the prompt exchange of relevant safety information with the responsible team. Their responsibilities may include source documentation, follow-up data, and periodic reporting. They should also provide information from healthcare professionals and other relevant sources.

The agreement should identify how information moves between the parties. This includes commercial, clinical, medical, and operational channels. Clear requirements reduce the risk of delays or incomplete transfers.

The Role of the QPPV

The qualified person responsible for pharmacovigilance should have appropriate oversight of the processes covered by the agreement. The QPPV should have sufficient visibility over outsourced work and partner processes. This supports effective oversight and allows potential gaps to be identified promptly.

The qualified person should also be able to access relevant information when assessing safety concerns. Clear escalation routes help maintain effective governance across the organisation.

Safety Data Exchange Timelines

Clear timelines are essential for controlled information flow between organisations. The agreement should establish appropriate time frames for case transmission, escalation, and regulatory reporting.

Case Transmission Timelines

The agreement should specify deadlines for initial cases and follow-up information. It should also define requirements for urgent safety issues. These timelines should reflect the nature and urgency of the information received.

The reconciliation process should be defined where multiple parties exchange case information. This helps identify missing data, discrepancies, or differences between records. Clear deadlines also support the timely completion of internal processing.

Escalation Procedures

Escalation procedures should address missed deadlines, incomplete information, and urgent safety concerns. The agreement should define who must be notified and how quickly escalation should occur.

Explicit procedures help prevent important information from remaining unresolved. They should also explain the expected response when a party fails to meet its agreed-upon responsibilities.

Reporting Coordination

The agreement should clarify who prepares each regulatory submission and who reviews the information before submission. It should also define communication with the relevant authorities where applicable.

The process should distinguish routine reporting from urgent communications. This coordination helps avoid duplicated work and supports consistent regulatory interactions.

Common Challenges When Managing Safety Data Exchange

Managing safety information across several organisations can create operational challenges. Responsibilities may become unclear, while agreements can become outdated after organisational or business changes. Different vendors may also use inconsistent terminology or processes.

Literature surveillance can generate information that requires assessment by different teams. A lack of clear ownership may delay evaluation and escalation. Similar issues can occur when medical information, product complaints, or other sources enter the process.

Regular review of contractual arrangements can help address these risks. Organisations may also use pharmacovigilance audit services to assess whether agreed processes are implemented effectively. Audits can identify gaps requiring corrective or preventive action.

How to Create an Effective Safety Data Exchange Agreement

A practical checklist can help ensure that the agreement covers key operational and regulatory requirements.

Step	What to define	Key points to check
1. Clearly define the scope	Products, territories, and partners	Include risk management plans, relevant markets, distribution arrangements, and the legal entity covered
2. Assign responsibilities	Sender, receiver, processor, and reporter	Define data collection, assessment, follow-up, escalation, and communication responsibilities
3. Establish timelines	Initial cases, follow-ups, and urgent issues	Set deadlines according to the type and urgency of information received
4. Maintain regular review	Regulatory, business, and product changes	Update the agreement when requirements, organisational arrangements, or products change

The agreement should serve as a legally binding contract while remaining practical for daily operations. The legal department should review contractual provisions before implementation. Regular review also helps align responsibilities with changing business and regulatory requirements.

Safety Data Exchange Agreements as a Foundation of Effective Pharmacovigilance Collaboration

An effective SDEA in pharmacovigilance is more than a contractual document. It provides an operational framework for controlled information exchange across the PV system. Clear responsibilities and timelines support collaboration between pharmaceutical industry stakeholders and external partners. They also help organisations meet expectations under EU drug safety regulations and FDA legislation. When agreements are well structured and regularly reviewed, they support consistent safety processes across partners, markets, and service providers. Ultimately, effective collaboration helps organisations identify important safety issues, meet their legal obligations, and contribute to ensuring patient safety.